Literature DB >> 19883419

Intravenous immunoglobulins--understanding properties and mechanisms.

A Durandy1, S V Kaveri, T W Kuijpers, M Basta, S Miescher, J V Ravetch, R Rieben.   

Abstract

High-dose intravenous immunoglobulin (IVIg) preparations are used currently for the treatment of autoimmune or inflammatory diseases. Despite numerous studies demonstrating efficacy, the precise mode of action of IVIg remains unclear. Paradoxically, IgG can exert both pro- and anti-inflammatory activities, depending on its concentration. The proinflammatory activity of low-dose IVIg requires complement activation or binding of the Fc fragment of IgG to IgG-specific receptors (FcgammaR) on innate immune effector cells. In contrast, when administered in high concentrations, IVIg has anti-inflammatory properties. How this anti-inflammatory effect is mediated has not yet been elucidated fully, and several mutually non-exclusive mechanisms have been proposed. This paper represents the proceedings of a session entitled 'IVIg--Understanding properties and mechanisms' at the 6th International Immunoglobulin Symposium that was held in Interlaken on 26-28 March 2009. The presentations addressed how IgG may affect the cellular compartment, evidence for IVIg-mediated scavenging of complement fragments, the role of the dimeric fraction of IVIg, the anti-inflammatory properties of the minor fraction of sialylated IgG molecules, and the genetic organization and variation in FcgammaRs. These findings demonstrate the considerable progress that has been made in understanding the mechanisms of action of IVIgs, and may influence future perspectives in the field of Ig therapy.

Mesh:

Substances:

Year:  2009        PMID: 19883419      PMCID: PMC2801035          DOI: 10.1111/j.1365-2249.2009.04022.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  72 in total

1.  The antiinflammatory IgG.

Authors:  Srini V Kaveri; Sébastien Lacroix-Desmazes; Jagadeesh Bayry
Journal:  N Engl J Med       Date:  2008-07-17       Impact factor: 91.245

Review 2.  Ambivalent effect of immunoglobulins on the complement system: activation versus inhibition.

Authors:  Milan Basta
Journal:  Mol Immunol       Date:  2008-08-15       Impact factor: 4.407

Review 3.  Modulation of the cellular immune system by intravenous immunoglobulin.

Authors:  Thanyalak Tha-In; Jagadeesh Bayry; Herold J Metselaar; Srini V Kaveri; Jaap Kwekkeboom
Journal:  Trends Immunol       Date:  2008-10-14       Impact factor: 16.687

Review 4.  What is the contents of the magic draft IVIg?

Authors:  Jean-François Seite; Yehuda Shoenfeld; Pierre Youinou; Sophie Hillion
Journal:  Autoimmun Rev       Date:  2008-05-02       Impact factor: 9.754

Review 5.  Natural anti-Siglec autoantibodies mediate potential immunoregulatory mechanisms: implications for the clinical use of intravenous immunoglobulins (IVIg).

Authors:  Stephan von Gunten; Hans-Uwe Simon
Journal:  Autoimmun Rev       Date:  2008-04-18       Impact factor: 9.754

6.  Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

Authors:  Robert M Anthony; Falk Nimmerjahn; David J Ashline; Vernon N Reinhold; James C Paulson; Jeffrey V Ravetch
Journal:  Science       Date:  2008-04-18       Impact factor: 47.728

Review 7.  The role of the complement cascade in ischemia/reperfusion injury: implications for neuroprotection.

Authors:  A L D'Ambrosio; D J Pinsky; E S Connolly
Journal:  Mol Med       Date:  2001-06       Impact factor: 6.354

Review 8.  Genetic susceptibility to autoimmune disorders: clues from gene association and gene expression studies.

Authors:  Ilse Gutierrez-Roelens; Bernard R Lauwerys
Journal:  Curr Mol Med       Date:  2008-09       Impact factor: 2.222

Review 9.  Immunoglobulin in the control of complement action.

Authors:  M M Frank; V D Miletic; H Jiang
Journal:  Immunol Res       Date:  2000       Impact factor: 4.505

10.  Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake.

Authors:  Lisa C Willcocks; Paul A Lyons; Menna R Clatworthy; James I Robinson; Wanling Yang; Stephen A Newland; Vincent Plagnol; Naomi N McGovern; Alison M Condliffe; Edwin R Chilvers; Dwomoa Adu; Elaine C Jolly; Richard Watts; Yu Lung Lau; Ann W Morgan; Gerard Nash; Kenneth G C Smith
Journal:  J Exp Med       Date:  2008-06-16       Impact factor: 14.307

View more
  64 in total

Review 1.  Multifarious roles of sialic acids in immunity.

Authors:  Ajit Varki; Pascal Gagneux
Journal:  Ann N Y Acad Sci       Date:  2012-04       Impact factor: 5.691

Review 2.  The role of sialic acid as a modulator of the anti-inflammatory activity of IgG.

Authors:  Sybille Böhm; Inessa Schwab; Anja Lux; Falk Nimmerjahn
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

3.  Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins.

Authors:  Hicham Bouhlal; Denis Martinvalet; Jean-Luc Teillaud; Catherine Fridman; Michel D Kazatchkine; Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2014-04-01       Impact factor: 8.317

Review 4.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

Review 5.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 6.  Polyvalent immunoglobulins: challenges and perspectives.

Authors:  Isabella Quinti; Serelina Coluzzi; Federica Pulvirenti; Alessandro Prezzo; Gabriella Girelli
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

7.  The case for immunomodulatory approaches in treating HSV encephalitis.

Authors:  Chandran Ramakrishna; Harry Openshaw; Edouard M Cantin
Journal:  Future Virol       Date:  2013-03-01       Impact factor: 1.831

8.  Fcγ receptor III and Fcγ receptor IV on macrophages drive autoimmune valvular carditis in mice.

Authors:  Patricia M Hobday; Jennifer L Auger; Gregory R Schuneman; Stefanie Haasken; J Sjef Verbeek; Bryce A Binstadt
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

Review 9.  RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).

Authors:  Jenny M Despotovic; Michele P Lambert; Jay H Herman; Terry B Gernsheimer; Keith R McCrae; Michael D Tarantino; James B Bussel
Journal:  Transfusion       Date:  2011-10-07       Impact factor: 3.157

10.  Reconstituted human polyclonal plasma-derived secretory-like IgM and IgA maintain the barrier function of epithelial cells infected with an enteropathogen.

Authors:  Stéphanie Longet; Cédric Vonarburg; Marius Lötscher; Sylvia Miescher; Adrian Zuercher; Blaise Corthésy
Journal:  J Biol Chem       Date:  2014-06-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.